Class information for:
Level 1: SIBUTRAMINE//ORLISTAT//ANTIOBESITY DRUGS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
8637 1164 42.5 76%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
683 12451 SIBUTRAMINE//ORLISTAT//WEIGHT LOSS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 SIBUTRAMINE Author keyword 302 67% 24% 274
2 ORLISTAT Author keyword 150 52% 17% 203
3 ANTIOBESITY DRUGS Author keyword 20 66% 2% 19
4 PHENTERMINE Author keyword 17 36% 3% 39
5 OBES CLIN TRIALS PROGRAM Address 17 100% 1% 8
6 LORCASERIN Author keyword 15 47% 2% 24
7 CONTRAVE Author keyword 11 78% 1% 7
8 SIBUTRAMINE HYDROCHLORIDE Author keyword 11 78% 1% 7
9 ANTI OBESITY AGENTS Author keyword 10 40% 2% 19
10 XENICAL Author keyword 9 67% 1% 8

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 SIBUTRAMINE 302 67% 24% 274 Search SIBUTRAMINE Search SIBUTRAMINE
2 ORLISTAT 150 52% 17% 203 Search ORLISTAT Search ORLISTAT
3 ANTIOBESITY DRUGS 20 66% 2% 19 Search ANTIOBESITY+DRUGS Search ANTIOBESITY+DRUGS
4 PHENTERMINE 17 36% 3% 39 Search PHENTERMINE Search PHENTERMINE
5 LORCASERIN 15 47% 2% 24 Search LORCASERIN Search LORCASERIN
6 CONTRAVE 11 78% 1% 7 Search CONTRAVE Search CONTRAVE
7 SIBUTRAMINE HYDROCHLORIDE 11 78% 1% 7 Search SIBUTRAMINE+HYDROCHLORIDE Search SIBUTRAMINE+HYDROCHLORIDE
8 ANTI OBESITY AGENTS 10 40% 2% 19 Search ANTI+OBESITY+AGENTS Search ANTI+OBESITY+AGENTS
9 XENICAL 9 67% 1% 8 Search XENICAL Search XENICAL
10 ANTIOBESITY AGENTS 7 57% 1% 8 Search ANTIOBESITY+AGENTS Search ANTIOBESITY+AGENTS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CONTROLLED RELEASE PHENTERMINE TOPIRAMATE 78 83% 4% 44
2 SIBUTRAMINE 60 38% 11% 128
3 LIPASE INHIBITOR 58 63% 5% 58
4 ORLISTAT 46 34% 9% 109
5 DIETARY FAT ABSORPTION 34 65% 3% 32
6 GASTROINTESTINAL LIPASE INHIBITOR 21 69% 2% 18
7 SUFFERING ESSENTIAL OBESITY 18 89% 1% 8
8 CANNABINOID 1 RECEPTOR BLOCKER 16 25% 5% 56
9 SCOUT TRIAL 15 88% 1% 7
10 OVERWEIGHT ADULTS 14 36% 3% 31

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Long-term Drug Treatment for Obesity A Systematic and Clinical Review 2014 67 70 71%
Orlistat-associated adverse effects and drug interactions - A critical review 2008 66 104 66%
Long-term effects of weight-reducing drugs in hypertensive patients 2009 29 57 82%
Drug therapy - Obesity 2002 374 73 33%
New Medications for Treatment of Obesity: Metabolic and Cardiovascular Effects 2015 3 85 34%
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date 2014 8 45 69%
Drug treatment of obesity: Current status and future prospects 2015 1 28 71%
Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis 2009 32 40 63%
Orlistat: A review of its use in the management of obesity 2006 35 90 80%
Anti-obesity drugs: a review about their effects and their safety 2012 43 66 50%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 OBES CLIN TRIALS PROGRAM 17 100% 0.7% 8
2 OBES CLIN TRIALS PROGRAMME 6 71% 0.4% 5
3 ENDOCRINOL OBES EATING DISORDERS GRP 4 75% 0.3% 3
4 COMPREHENS WEIGHT CONTROL PROGRAM 2 32% 0.5% 6
5 G DESCOVICH ATHEROSCLEROSIS STUDY 2 16% 0.9% 11
6 GRUNBERGER DIABET 1 50% 0.2% 2
7 NUTR WEIGHT MANAGEMENT 1 23% 0.4% 5
8 TRANSLAT METAB DIABET 1 15% 0.6% 7
9 CNS PHARMACOL PSYCHIAT 1 40% 0.2% 2
10 INTERNAL MED AGING KIDNEY DIS 1 11% 0.7% 8

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000196917 VALVULOPATHY//DRUG INDUCED VALVULAR DISEASE//ERGOT DERIVED DOPAMINE AGONISTS
2 0.0000176843 CYCLOCARYA PALIURUS//CYCLOCARYA PALIURUS BATAL ILJINSKAJA//PANCREATIC LIPASE
3 0.0000161021 DEXFENFLURAMINE//D FENFLURAMINE//FENFLURAMINE
4 0.0000141429 WEIGHT LOSS MAINTENANCE//SELF WEIGHING//WEIGHT MAINTENANCE
5 0.0000117900 RIMONABANT//TARANABANT//ENDOCANNABINOIDS
6 0.0000087233 SILDENAFIL ANALOGUE//TADALAFIL ANALOGUE//HOMOSILDENAFIL
7 0.0000080289 TOPIRAMATE//TOPIRAMATE TOPAMAX//TOPIRAMATE TOXICITY
8 0.0000061829 OBESITY PARADOX//HUMAN PERFORMANCE SPORT SCI//CARDIOVASC DISJOHN OCHSNER HEART VASC INS
9 0.0000060556 FUTURE PROGRAMS//JOHNS HOPKINS WEIGHT MANAGEMENT//MEDICAL FITNESS
10 0.0000054758 SYNEPHRINE//P SYNEPHRINE//EPHEDRINE